US Board Of Patent Appeals Denies Siemens Rehearing On Enzo Patent

Enzo Biochem ENZ today reported that the Board of Patent Appeals and Interferences of the United States Patent and Trademark Office has issued a Decision denying a Request for Rehearing filed by Siemens Healthcare Diagnostics SI in a patent interference proceeding relating to Enzo Life Science's application for nucleic acid signal amplification and Siemens U.S. Patent No. 5,124,246, relating to branched DNA diagnostic systems. Siemens filed the rehearing request in response to a February 22, 2010 Decision by the Patent Office awarding priority of the invention to Enzo. The result of this latest Decision is that the judgment of the Patent Office is now final. Subject to any appeals that Siemens might file in federal court, Enzo will receive a full 17-year patent for all the inventions covered by the claim, commencing on the date of the patent's issuance. "This technology is the basis for a number of significant products in clinical diagnostics and in the life sciences field which currently are marketed or licensed by various commercial entities," said Elazar Rabbani, PhD, Chairman and CEO of Enzo. "Additionally, we plan to expand the application of this key technology beyond the scope of gene-based applications into the field of immunodiagnostics." Learn how to find the best stocks to trade each day in our 70 page E-Book and 90 minute online videofor free.